How Does Arynta Work for Binge Eating Disorder? The main ingredient in Arynta is lisdexamfetamine, a central nervous system (CNS) stimulant. It is not clear how lisdexamfetamine works for binge eating ...

Findings from the interviews offer insight into potential strategies for reducing binge eating among patients who experience food insecurity. Inconsistent food access, mental and physical health, and ...

The New York Times describes the new movement uniting the obese and people with eating disorders. The issue that unites them is binge eating—an addictive behavior. Not all obese people are binge ...

When people binge eat, it's rarely broccoli or apples on the menu. Instead, foods like cake, cookies, ice cream and chocolate ...

A new model was linked to decreased BMI, caloric intake, and loss of control eating in veterans with binge eating disorders or subjective binge eating episodes. A new model to treat binge eating ...

Add Yahoo as a preferred source to see more of our stories on Google. (Diana Ramirez/De Los) Food always powered Anahi Araiza through study sessions and cultural gatherings. But after putting on some ...

Patients taking a commonly used stimulant for the treatment of binge eating disorder experienced mixed results, according to Rutgers Health researchers. Binge eating disorder is the most common eating ...

Ultra-processed foods are dangerous to our physical and mental health, contributing to obesity, diabetes, heart disease, eating disorders, anxiety, and depression.

Almost 1 in 10 patients receiving HIV care may have binge eating disorder (BED), a significantly higher rate than the 0.3% reported in the general population, according to a cross-sectional study.

Binge eating, especially on high-fat, high-sugar foods, can rewire the brain and alter behaviour, leading to compulsive food-seeking and a greater likelihood of overeating instead of undereating when ...

Medications like Ozempic are not going anywhere anytime soon. Subscribe to our newsletter for the latest sci-tech news updates. Twelve percent of US adults have taken a GLP-1 agonist—an increasingly ...